StockData
Haemonetics Corp logo

Haemonetics Corp (HAE) stock

HAENYSESurgical & Medical Instruments & ApparatusFiscal year ends April 3
Financials through Q2 FY2027, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3064% above fair value
$122.94+0.23 (+0.19%)

Close on Nov 13, 2026Market cap $5.59BP/E 54.9Yield –

Earnings

Haemonetics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 4, 2027
Q3 FY2027 · estimated, before the open
Revenue, Q2 FY2027
$357.80M
+9.3% on a year earlier
adjusted earnings per diluted share, Q2 FY2027
$1.35
$1.27 a year earlier
Latest guidance
Issued
Nov 5, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Haemonetics's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2027ended Dec 27, 2026Feb 4, 2027Expected–––––
Q2 FY2027ended Sep 26, 2026Nov 5, 2026before the open$357.80M+9.3%$1.00$1.35Release
Q1 FY2027ended Jun 27, 2026Aug 6, 2026before the open$339.40M+5.6%$0.72$1.14Release
Q4 FY2026ended Mar 28, 2026May 7, 2026before the open$346.40M+4.8%-$0.44$1.29Release
Q3 FY2026ended Dec 27, 2025Feb 5, 2026before the open$339.00M-2.7%$0.95$1.31Release
Q2 FY2026ended Sep 27, 2025Nov 6, 2025before the open$327.30M-5.3%$0.81$1.27Release
Q1 FY2026ended Jun 28, 2025Aug 7, 2025before the open$321.40M-4.4%$0.70$1.10Release
Q4 FY2025ended Mar 29, 2025May 8, 2025before the open$330.60M-3.7%$1.17$1.24Release
Q3 FY2025ended Dec 28, 2024Feb 6, 2025before the open$348.50M+3.6%$0.74$1.19Release
Q2 FY2025ended Sep 28, 2024Nov 7, 2024before the open$345.50M+8.6%$0.66$1.12Release
Q1 FY2025ended Jun 29, 2024Aug 8, 2024before the open$336.20M+8.0%$0.74$1.02Release
Q4 FY2024ended Mar 30, 2024May 9, 2024before the open$343.30M+12.8%$0.40$0.90Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Haemonetics's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Organic Revenuenon-GAAPFY2027+6% – +9%–NewNov 5, 2026
Organic Revenuenon-GAAPFY2027+3% – +6%–NewMay 7, 2026
Reported RevenueGAAPFY2027+8% – +11%–NewNov 5, 2026
Reported RevenueGAAPFY2027+4% – +7%–NewMay 7, 2026
Free cash flow conversionnon-GAAPFY202780%–NewMay 7, 2026

Guidance vs results

The last range Haemonetics gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2026Adjusted earnings per diluted share$4.70 – $5.00$4.97Σ4QWithin range

Guidance history

Every forecast Haemonetics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 5, 2026Reported RevenueFY2027+8% – +11%New
Nov 5, 2026Organic RevenueFY2027+6% – +9%New
May 7, 2026Free cash flow conversionFY202780%New
May 7, 2026Reported RevenueFY2027+4% – +7%New
May 7, 2026Organic RevenueFY2027+3% – +6%New
Aug 7, 2025Adjusted earnings per diluted shareFY2026$4.70 – $5.00New
Aug 7, 2025Free cash flowFY2026$160.00M – $200.00MNew
Aug 7, 2025Adjusted operating marginFY202626% – 27%New
Aug 8, 2024Adjusted earnings per diluted shareFY2025$4.45 – $4.75Reaffirmed
Aug 8, 2024Free cash flowFY2025$130.00M – $180.00MReaffirmed
Aug 8, 2024Adjusted operating marginFY202523% – 24%Reaffirmed
Aug 8, 2024ReportedFY2025+5% – +8%Reaffirmed
Aug 8, 2024OrganicFY20250% – +3%Reaffirmed
May 9, 2024Adjusted earnings per diluted shareFY2025$4.45 – $4.75New
May 9, 2024Free cash flowFY2025$130.00M – $180.00MNew
May 9, 2024Adjusted operating marginFY202523% – 24%New
May 9, 2024ReportedFY2025+5% – +8%New
May 9, 2024OrganicFY20250% – +3%New
Feb 8, 2024Adjusted earnings per diluted shareFY2024$3.90 – $4.00Raised
Feb 8, 2024Free cash flow, before restructuring & restructuring related costsFY2024$160.00M – $180.00MLowered

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Haemonetics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Olga Guyette, Vice President-Investor Relations & Treasury
    Results
  2. Olga Guyette, Vice President-Investor Relations & Treasury
    Results
  3. Olga Guyette, Vice President - Investor Relations & Treasury
    Update
  4. Olga Guyette, Vice President-Investor Relations & Treasury
    Results
  5. Olga Guyette, Vice President-Investor Relations & Treasury
    Results
  6. Olga Guyette, VP-Investor Relations & Treasury
    News
  7. Olga Guyette, Vice President-Investor Relations & Treasury
    Results
  8. Olga Guyette, Vice President-Investor Relations & Treasury
    Results
  9. Olga Guyette, Vice President-Investor Relations & Treasury
    Results
  10. Olga Guyette, Vice President-Investor Relations & Treasury
    Update
  11. Olga Guyette, Vice President-Investor Relations & Treasury
    Results
  12. Olga Guyette, Vice President-Investor Relations & Treasury
    News
  13. Olga Guyette, Vice President-Investor Relations & Treasury
    News
  14. Olga Guyette, Vice President-Investor Relations & Treasury
    Results
  15. Olga Guyette, Vice President-Investor Relations & Treasury
    Results

See a number that looks wrong?